Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.02
(4.18%)
SEK 0.02
(4.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.26 Million SEK | 161.43% |
| 2022 | 2.77 Million SEK | 29.52% |
| 2021 | 2.14 Million SEK | 98.52% |
| 2020 | 1.08 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 2.45 Million SEK | -13.42% |
| 2024 Q1 | 10.25 Million SEK | 41.28% |
| 2024 Q2 | 2.83 Million SEK | -72.39% |
| 2023 FY | 7.26 Million SEK | 161.43% |
| 2023 Q4 | 7.26 Million SEK | 8.44% |
| 2023 Q3 | 6.69 Million SEK | 77.3% |
| 2023 Q2 | 3.77 Million SEK | -3.99% |
| 2023 Q1 | 3.93 Million SEK | 41.63% |
| 2022 FY | 2.77 Million SEK | 29.52% |
| 2022 Q4 | 2.77 Million SEK | -64.78% |
| 2022 Q3 | 7.88 Million SEK | -2.55% |
| 2022 Q2 | 8.09 Million SEK | 265.28% |
| 2022 Q1 | 2.21 Million SEK | 3.31% |
| 2021 Q1 | 1.32 Million SEK | 22.41% |
| 2021 FY | 2.14 Million SEK | 98.52% |
| 2021 Q3 | 1.61 Million SEK | -85.39% |
| 2021 Q2 | 11.05 Million SEK | 735.93% |
| 2021 Q4 | 2.14 Million SEK | 32.84% |
| 2020 Q4 | 1.08 Million SEK | 0.0% |
| 2020 FY | 1.08 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 93.189% |
| Ziccum AB (publ) | 6.38 Million SEK | -13.651% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -207.758% |
| BioArctic AB (publ) | 139.5 Million SEK | 94.796% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 79.019% |
| Mendus AB (publ) | 51.22 Million SEK | 85.827% |
| Genovis AB (publ.) | 98.04 Million SEK | 92.595% |
| Intervacc AB (publ) | 21.68 Million SEK | 66.513% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 72.817% |
| Active Biotech AB (publ) | 13.4 Million SEK | 45.821% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 94.144% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 54.954% |
| Aptahem AB (publ) | 8.99 Million SEK | 19.314% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 82.232% |
| Kancera AB (publ) | 17.97 Million SEK | 59.617% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 84.279% |
| Fluicell AB (publ) | 8.91 Million SEK | 18.564% |
| Saniona AB (publ) | 86.08 Million SEK | 91.566% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -40.752% |
| Biovica International AB (publ) | 34.76 Million SEK | 79.118% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 37.779% |
| AcouSort AB (publ) | 10.37 Million SEK | 30.044% |
| Xintela AB (publ) | 14.01 Million SEK | 48.198% |
| Abliva AB (publ) | 16.78 Million SEK | 56.737% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 96.617% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 37.246% |
| OncoZenge AB (publ) | 1.69 Million SEK | -327.31% |
| Amniotics AB (publ) | 10.54 Million SEK | 31.165% |
| 2cureX AB (publ) | 2.93 Million SEK | -147.359% |
| CombiGene AB (publ) | 4.15 Million SEK | -74.687% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -64.031% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.536% |
| Camurus AB (publ) | 414.81 Million SEK | 98.25% |
| Corline Biomedical AB | 6.78 Million SEK | -6.938% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 88.168% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 62.116% |
| I-Tech AB | 16.2 Million SEK | 55.199% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.388% |
| Cyxone AB (publ) | 4.69 Million SEK | -54.666% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 45.528% |
| Biosergen AB | 5.08 Million SEK | -42.773% |
| Cantargia AB (publ) | 54.97 Million SEK | 86.793% |
| NextCell Pharma AB | 13.68 Million SEK | 46.965% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 89.896% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 47.283% |
| Nanologica AB (publ) | 79.32 Million SEK | 90.848% |
| SynAct Pharma AB | 51.83 Million SEK | 85.994% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 8.668% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -39.751% |
| LIDDS AB (publ) | 3.75 Million SEK | -93.291% |
| Lipum AB (publ) | 7.53 Million SEK | 3.688% |
| BioInvent International AB (publ) | 90.45 Million SEK | 91.974% |
| Alzinova AB (publ) | 9.33 Million SEK | 22.195% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 96.002% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -304.682% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 60.744% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -89.161% |
| Simris Alg AB (publ) | 148.93 Million SEK | 95.125% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 89.792% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.494% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 43.032% |